Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P81274
UPID:
GPSM2_HUMAN
Alternative names:
Mosaic protein LGN
Alternative UPACC:
P81274; Q5T1N8; Q6IBL7; Q8N0Z5
Background:
G-protein-signaling modulator 2, also known as Mosaic protein LGN, is pivotal in mitotic spindle pole organization through its interaction with NUMA1. It is essential for metaphase spindle orientation and plays a crucial role in asymmetric cell divisions. Additionally, it exhibits GDI activity towards G(i) alpha proteins, regulating their activity.
Therapeutic significance:
Linked to Chudley-McCullough syndrome, a neurologic disorder with early-onset sensorineural deafness and specific brain anomalies, understanding the role of G-protein-signaling modulator 2 could open doors to potential therapeutic strategies.